TY - JOUR
T1 - Dose-related effects of nebulized metaproterenol in asthmatic children
AU - Crain, Ellen F.
AU - Gershel, Jeffrey C.
AU - Kadar, Avrom
AU - Kastner, Theodore
PY - 1987/9
Y1 - 1987/9
N2 - The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25–75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25–75 less than 80% of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25–75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.
AB - The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25–75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25–75 less than 80% of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25–75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.
UR - http://www.scopus.com/inward/record.url?scp=0023607961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023607961&partnerID=8YFLogxK
U2 - 10.1097/00006565-198709000-00001
DO - 10.1097/00006565-198709000-00001
M3 - Article
C2 - 3671137
AN - SCOPUS:0023607961
SN - 0749-5161
VL - 3
SP - 143
EP - 146
JO - Pediatric Emergency Care
JF - Pediatric Emergency Care
IS - 3
ER -